BridgeBio Pharma, Inc. (BBIO) SEC Filings, May 8-19, 2026

BridgeBio Pharma, Inc. Chief Executive Officer Neil Kumar reported routine equity compensation activity involving Restricted Stock Units (RSUs) and related tax withholding. On May 16, 2026, RSUs covering 71,215 shares of common stock vested and were converted into shares, as reflected by multiple M-code derivative exercises. A total of 36,236 shares of common stock were disposed of under code F at $66.13 per share to satisfy tax obligations, not as an open-market sale, leaving 269,430 common shares held directly. Kumar also has indirect interests in 4,358,447 common shares held by the Kumar Haldea Revocable Trust and 555,686 shares held by the Kumar Haldea Family Irrevocable Trust, with beneficial ownership of these trust holdings disclaimed except to the extent of any pecuniary interest.

BridgeBio Pharma, Inc. Chief Accounting Officer Maricel Apuli reported a share disposition tied to tax withholding on vested equity awards. On May 16, 2026, 4,714 shares of common stock were withheld at $66.13 per share to satisfy her tax obligation on the vesting of 9,260 RSU-based shares. After this withholding, she directly held 129,401 shares of BridgeBio common stock. This type of transaction is used to cover taxes on compensation-related stock vesting rather than representing an open‑market sale.

BridgeBio Pharma director Scott Randal W. exercised stock options for 10,000 shares of common stock at $16.75 per share and sold 10,000 shares in open-market transactions on May 15, 2026. The sales occurred in multiple trades at weighted average prices around the high‑$60 range under a pre-arranged Rule 10b5-1 sales plan. Following these transactions, he holds 11,589 shares directly and 4,000 shares indirectly through Thinking Bench Capital LLC.

Janus Henderson Group plc filed an amendment to a Schedule 13G reporting beneficial ownership of 13,179,013 shares of BridgeBio Pharma, Inc. Common Stock, representing 6.8% of the class as shown with a 03/31/2026 date line. The filing states the Asset Managers exercise shared voting and dispositive power over these shares (each listed with 13,179,013 votes/ dispositive power) and includes a disclaimer that the Asset Managers do not have rights to dividends or sale proceeds for the managed accounts. The filing was signed by Kristin Mariani as Head of North America Compliance on 5/15/2026 and references Exhibit 99 for Item 7 details.

BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret as a targeted treatment for autosomal dominant hypocalcemia type 1 (ADH1). In the Phase 3 CALIBRATE trial, encaleret met all pre-specified primary and key secondary efficacy endpoints.

At Week 24, 76% of participants on encaleret achieved both serum and urine calcium within target ranges, compared with 4% on conventional therapy at Week 4 (p<0.0001). The company states that encaleret may be eligible for priority review and that it anticipates a potential U.S. launch in early 2027, if approved.

BridgeBio plans additional regulatory and development steps, including a Marketing Authorization Application to the EMA for ADH1 in the second half of 2026, ongoing enrollment of the CALIBRATE-PEDS pediatric ADH1 study, and initiation of the -HP Phase 3 study in chronic hypoparathyroidism in Summer 2026. Encaleret has Fast Track and Orphan Drug designations in multiple regions.

BridgeBio Pharma, Inc. CEO Neil Kumar reported insider sales executed through family trusts. Trusts associated with him sold a total of 80,000 shares of common stock in open-market transactions on May 7–8, 2026, at weighted average prices generally between about $66 and $69 per share, under a pre-arranged Rule 10b5-1 sales plan adopted on March 31, 2025. The sales were made by the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, where he serves as co-trustee and disclaims beneficial ownership beyond any pecuniary interest. After these transactions, Kumar still holds 234,451 shares of common stock directly as of May 7, 2026, in addition to substantial indirect trust holdings.

BridgeBio Pharma, Inc. entered into a new Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC to establish an at-the-market stock offering program. The company may sell, at its discretion, shares of common stock with an aggregate offering price of up to $500,000,000 through these sales agents on Nasdaq or other existing markets.

The sales agents will use commercially reasonable efforts on a best efforts basis, and BridgeBio will pay them a commission of up to 3.0% of gross proceeds on any shares sold. In connection with the new arrangement, BridgeBio and the agents agreed to terminate their prior Equity Distribution Agreement dated May 4, 2023, effective May 7, 2026.

BridgeBio Pharma filed a shelf registration and prospectus supplement to offer up to $500,000,000 of its common stock under an equity distribution agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC. Shares may be sold from time to time in at-the-market transactions, block trades or negotiated sales.

The prospectus highlights that on May 6, 2026 the closing price was $68.09 per share and provides an illustrative share count assuming sales of 7,343,222 shares. Use of proceeds is for general corporate purposes, including R&D, commercialization of Attruby, working capital and potential investments.